DelveInsight’s, “Chronic Myelomonocytic Leukaemia Pipeline Insight 2023” report provides comprehensive insights about 25+ companies and 27+ pipeline drugs in the Chronic Myelomonocytic Leukaemia pipeline landscape. It covers the Chronic Myelomonocytic Leukaemia pipeline drug profiles, including Chronic Myelomonocytic Leukaemia clinical trials and nonclinical stage products. It also covers the Chronic Myelomonocytic Leukaemia therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Recent Developmental Activities in the Chronic Myelomonocytic Leukaemia Treatment Landscape
Request a sample and discover the recent breakthroughs happening in the Chronic Myelomonocytic Leukaemia Pipeline landscape @ Chronic Myelomonocytic Leukaemia Pipeline Outlook
Chronic Myelomonocytic Leukaemia Overview
CMML is a form of leukaemia that is characterised by high numbers of white blood cells, called ‘monocytes’, in the blood and bone marrow. CMML is an uncommon blood cancer with features of two other types of blood cancer. Even though it has leukaemia as part of its name, the World Health Organisation (WHO) classifies CMML as a ‘mixed myelodysplastic (MDS) myeloproliferative neoplasm (MPN)’. MPN is a group of disorders of the bone marrow stem cells that produce excess numbers of one or more types of blood cells (red cells, white cells, or platelets).
Key Takeaways from the Chronic Myelomonocytic Leukaemia Pipeline Report
For further information, refer to the detailed Chronic Myelomonocytic Leukaemia Drugs Launch, Chronic Myelomonocytic Leukaemia Developmental Activities, and Chronic Myelomonocytic Leukaemia News, click here for Chronic Myelomonocytic Leukaemia Ongoing Clinical Trial Analysis
Chronic Myelomonocytic Leukaemia Emerging Drugs Profile
Sabatolimab (MBG 453) is an anti T-cell immunoglobulin and mucin domain 3 (anti-TIM3) monoclonal antibody that is being developed by Novartis Oncology. The drug is currently in phase III stage of development for the treatment of Chronic Myelomonocytic Leukaemia.
Lenzilumab is a monoclonal antibody, which acts a granulocyte macrophage colony stimulating factor antagonists. Lenzilumab is well tolerated in patients with CMML, with no grade 3 or 4 treatment emergent adverse events or DLTs reported. The favorable safety and activity profile of lenzilumab warrants future evaluation as part of a combination regimen targeted to specific subtypes more likely to respond, including patients with NRAS mutations. The drug is currently in phase 2/3 stage of development for the treatment of CMML.
Jakafi is a first-in-class inhibitor of the JAK1 and JAK2 protein kinases and works by competitively inhibiting the ATP-binding catalytic site on JAK1 and JAK2. The result of this inhibition is disruption of cytokine and growth factor signaling pathways, leading to a decrease in proinflammatory cytokines and chemokines. In the clinical study, Ruxoltinib demonstrated meaningful clinical activity in CMML patients with splenomegaly and/or high disease symptom burden. The drug is already approved by the US Food and Drug Administration for the treatment of people with intermediate or high-risk myelofibrosis (MF), including primary MF, post–polycythemia vera MF, and post–essential thrombocythemia MF. Jakafi is also indicated for the treatment of people with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea. The drug is currently in Phase II stage of development for the treatment of Chronic Myelomonocytic Leukaemia.
NMS-03592088 (NMS-088) is a potent inhibitor of FLT3, KIT, and CSF1R kinases. NMS-088 is the most active compound among the FLT3 comparators, a finding especially evident in the presence of the FLT3 “gatekeeper mutation,” which is associated with clinical resistance to treatment with other FLT3 inhibitors. There is a rationale for the use of the molecule in Chronic Myelomonocytic Leukemia (CMML) on the basis of the demonstrated inhibition of CSF1R, a highly expressed and activated target in this tumor type. The drug is currently in the Phase I/II stage of development for the treatment of CMML.
LP-108 is a proto-oncogene protein (c-bcl-2) inhibitor. The drug is currently in Phase I stage of development for the treatment of CMML.
Chronic Myelomonocytic Leukaemia Pipeline Therapeutics Assessment
There are approx. 25+ key companies which are developing the therapies for Diffuse Large B-Cell Lymphoma. The companies which have their Chronic Myelomonocytic Leukaemia drug candidates in the most advanced stage, i.e. phase III include, Novartis.
Find out more about the Chronic Myelomonocytic Leukaemia Pipeline Segmentation, Therapeutics Assessment, and Chronic Myelomonocytic Leukaemia Emerging Drugs @ Chronic Myelomonocytic Leukaemia Treatment Landscape
Scope of the Chronic Myelomonocytic Leukaemia Pipeline Report
Dive deep into rich insights for drugs for Chronic Myelomonocytic Leukaemia Pipeline Companies and Therapies, click here @ Chronic Myelomonocytic Leukaemia Unmet Needs and Analyst Views
Table of Content
Got Queries? Find out the related information on Chronic Myelomonocytic Leukaemia Mergers and acquisitions, Chronic Myelomonocytic Leukaemia Licensing Activities @ Chronic Myelomonocytic Leukaemia Recent Trends, and Future Perspectives
About Us
DelveInsight is a leading healthcare focussed market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/